4.3 Article

Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

期刊

JOURNAL OF SEXUAL MEDICINE
卷 17, 期 8, 页码 1579-1582

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.jsxm.2020.05.019

关键词

Erectile Dysfunction; Priapism; PDE5 Inhibitors; Men's Health

向作者/读者索取更多资源

Background: Priapism is an adverse drug reaction (ADR) associated with phosphodiesterase type 5 inhibitors (PDE5is) in the treatment of erectile dysfunction. Aim: The purpose of this study was to identify the true data about PDE5i-associated priapism to properly counsel patients. Methods: We queried the U.S. Food and Drug Administration (FDA) Adverse Reporting System Public Dashboard to identify cases of drug-induced priapism among medications commonly associated with priapism. Next, a systematic review and analysis of publications describing cases of drug-induced priapism were carried out. Outcomes: The main outome of this study is incidence of PDE5i-induced priapism. Results: We found 411 cases of drug-induced priapism secondary to Viagra, Cialis, or Levitra reported to the Food and Drug Administration since 1998. Compared with PDE5is, drug-induced priapism was 2.6 (n = 1,065) and 2.0 times (n = 817) more commonly reported for second-generation antipsychotics and the antidepressant/sleep aid trazodone, respectively. A total of 240 manuscripts describing cases of drug-induced priapism in patients with nonsickle cell disease were identified. PDE5i-induced priapism accounted for only 2.9% (n = 7) of drug-induced priapism cases. Second-generation antipsychotics (33.8%), a group of other medications (11.3%), and alphaadrenergic antagonists (8.8%) accounted for the greatest percentage of published drug-induced priapism cases. Clinical Implications: Extensive counseling about priapism as an ADR for PDE5i for the routine treatment of erectile dysfunction is likely unnecessary. Strengths & Limitations: The study used national-level data to identify drug-induced priapism cases. Reported and published cases of drug-induced priapism may reflect more severe and atypical cases of this ADR, which may have underestimated our results. Conclusion: PDE5i-induced priapism is a rare event. Drug-induced priapism should be attributed to a wider spectrum of medications that can cause this condition.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据